Adeno-associated viral vectors have been developed for the treatment of hemophilia A and B. Derivation of vector particles is achieved after multiplasmid transfection of cells that package the vector genome to yield vector particles. To date, three clinical trials have been performed for hemophilia B. The results of these trials are described. The trial that we conducted with our collaborators has yielded evidence of clinical efficacy for hemophilia B. A vector for treating hemophilia A has been developed and a clinical trial is planned.
Get full access to this article
View all access options for this article.
References
1.
StamatoyannopoulosG, NienhuisAW. Cellular and Molecular Regulation of Hemoglobin Switching. (Grune & Stratton, Inc., New York, NY). 1979.
2.
NathwaniAC, NienhuisAW, DavidoffAM. Our journey to successful gene therapy for hemophilia B. Hum Gene Ther, 2014; 25:923–926.
3.
DarbySC, KanSW, SpoonerRJ, et al.Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood, 2007; 110:815–825.
4.
NathwaniAC, HanawaH, VandergriffJ, et al.Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV. Gene Ther, 2000; 7:183–195.
5.
DavidoffAM, GrayJT, NgCYC, et al.Comparison of the ability of adeno-associated viral vectors pseudotyped with a serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther, 2005; 11:875–888.
6.
GaoG-P, AlviraMR, WangL, et al.Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Aacad Sci USA, 2002; 99:11854–11859.
7.
SamulskiRJ, ScrivastavaA, BernsKI, et al.Rescue of adeno-associated virus from recombinant plasmids: Gene correction within the terminal repeats of AAV. Cell, 1983; 33:135–143.
8.
KayMA, MannoCS, RagniMV, et al.Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet, 2000; 24:257–261.
9.
MannoCS, ChewAJ, HutchisonS, et al.AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood, 2003; 101:2963–2972.
10.
BuchlisG, PodsakoffGM, RaduA, et al.Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood, 2012; 119:3038–3041.
11.
MannoC, PierceG, ArrudaV, et al.Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–347.
12.
MingozziF, MausV, HuiD, et al.CD8+ T-cells responses to adeno-associated virus capsid in humans. Nat Med, 2007; 13:419–422.
13.
PienGC, Basner-TschakarjanE, HuiDJ, et al.Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest, 2009; 119:1688–1695.
14.
HurlbutGD, ZieglerRJ, NietupskiJB, et al.Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol Ther, 2010; 18:1983–1994.
15.
McIntoshJH, CochraneM, CobboldS, et al.Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther, 2012; 19:78–85.
16.
JiangH, CoutoLB, Patarroyo-WhiteS, et al.Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood, 2006; 108:3321–3328.
17.
ThomasCE, StormTA, HuangZ, et al.Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol, 2004; 78:3110–3122.
18.
McCartyDM, FuH, MonahanPE, et al.Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther, 2003; 10:2112–2118.
19.
WangZ, MaH-I, LiJ, et al.Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther, 2003; 10:2105–2111.
20.
NathwaniAC, GrayJT, NgCYC, et al.Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 2006; 107:2653–2661.
21.
NathwaniAC, GrayJT, McIntoshJ, et al.Safe and efficient transduction of the liver and peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood, 2007; 109:1414–1421.
22.
NathwaniAC, ReissUM, TuddenhamEGD, et al.Long-term safety and efficacy of Factor IX gene therapy in hemophilia B. N Engl J Med, 2014; 371:1994–2004.
23.
NathwaniAC, TuddenhamEG, RangaraianS, et al.Adeno-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 2011; 365:2357–2365.
24.
CrudeleJM, FinnJD, SinerJI, et al.AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood, 2015; 125:1553–1561.
25.
NairN, RinconMY, EvensH, et al.Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. Blood, 2014; 123:3195–3199.
26.
MonahanPE, SunJ, GuiT, et al.Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: Preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther, 2015; 26:69–81.
27.
McIntoshJ, LentingPJ, RosalesC, et al.Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood, 2013; 121:3335–3344.
